Summit Therapeutics Inc. SMMT
We take great care to ensure that the data presented and summarized in this overview for Summit Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMMT
View all-
Black Rock Inc. New York, NY9.82MShares$33.2 Million0.0% of portfolio
-
State Street Corp Boston, MA8.11MShares$27.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.27MShares$24.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.15MShares$10.7 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$3.63 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA1.02MShares$3.44 Million0.0% of portfolio
-
Morgan Stanley New York, NY693KShares$2.34 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY681KShares$2.3 Million0.0% of portfolio
-
Rafferty Asset Management, LLC New York, NY650KShares$2.2 Million0.01% of portfolio
-
Steward Partners Investment Advisory, LLC607KShares$2.05 Million0.03% of portfolio
Latest Institutional Activity in SMMT
Top Purchases
Top Sells
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Insider Transactions at SMMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2024
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
54,321
+14.35%
|
$162,963
$3.72 P/Share
|
|
Mar 27
2024
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
26,000
+4.75%
|
$78,000
$3.72 P/Share
|
|
Mar 26
2024
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
100,000
+21.98%
|
$300,000
$3.75 P/Share
|
|
Mar 26
2024
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
30,000
+50.0%
|
$90,000
$3.75 P/Share
|
|
Dec 13
2023
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
20,400
+3.73%
|
$40,800
$2.16 P/Share
|
|
Dec 12
2023
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.0%
|
$10,000
$2.07 P/Share
|
|
Dec 11
2023
|
Maky Zanganeh Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
315,681
+1.25%
|
$315,681
$1.58 P/Share
|
|
Dec 11
2023
|
Maky Zanganeh Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
489,814
+50.0%
|
$489,814
$1.44 P/Share
|
|
Oct 13
2023
|
Manmeet Singh Soni Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,976,190
+50.0%
|
$2,976,190
$1.68 P/Share
|
|
Mar 08
2023
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
7,553,301
+40.57%
|
$7,553,301
$1.05 P/Share
|
|
Mar 08
2023
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,973,743
+40.57%
|
$15,973,743
$1.05 P/Share
|
|
Mar 07
2023
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
196,362
+45.57%
|
$196,362
$1.05 P/Share
|
|
Mar 06
2023
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
376,489,880
+40.53%
|
$376,489,880
$1.05 P/Share
|
|
Dec 06
2022
|
Maky Zanganeh Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
373,857
+3.31%
|
-
|
|
Dec 06
2022
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
9,346,434
+5.16%
|
-
|
|
Aug 16
2022
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,624,702
+32.08%
|
$0
$0.97 P/Share
|
|
Aug 16
2022
|
Maky Zanganeh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
184,430
+33.88%
|
$0
$0.97 P/Share
|
|
Aug 16
2022
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
94,849,203
+36.85%
|
$0
$0.97 P/Share
|
|
Aug 16
2022
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
24,658
+39.23%
|
$0
$0.97 P/Share
|
|
Aug 16
2022
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
11,557
+23.29%
|
$0
$0.97 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 3.21M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 805K shares |